Literature DB >> 26624899

Verbal Fluencies and Fampridine Treatment in Multiple Sclerosis.

Eloi Magnin1, Yoshimasa Sagawa, Ludivine Chamard, Eric Berger, Thierry Moulin, Pierre Decavel.   

Abstract

BACKGROUND/AIMS: Fampridine is sometimes reported to improve cognition and especially the information-processing speed. Motor improvement might be a confounding factor. The aim of this study was to evaluate the effects of fampridine on verbal fluencies in patients with multiple sclerosis (MS).
METHODS: Fifty MS patients were included in a prospective monocentric open label trial with a mean Expanded Disability Status Scale of 5.3 ± 1.1. Assessments of verbal phonological and semantic fluencies were repeated twice (within 1 week) before fampridine treatment and twice after fampridine treatment in order to have the maximal practice effect. Gait velocity and fatigue (visual analogical scale) were also assessed. Distribution into gait responders, gait non-responders, fluency responders and fluency non-responders, was described.
RESULTS: Verbal fluencies were significantly higher after fampridine treatment. No correlation was observed between phonological fluency improvement and semantic fluency improvement. Gait responders and gait non-responders did not present significant differences in verbal fluency performance and fatigue score. No correlation between gait velocity improvement and fatigue improvement compared with verbal fluency improvement was observed.
CONCLUSION: Our results suggest that fampridine could have a selective procognitive effect on phonological fluency in MS, even in the gait non-responder patients.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26624899     DOI: 10.1159/000442348

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  6 in total

Review 1.  Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis.

Authors:  Maxime Valet; Mélanie Quoilin; Thierry Lejeune; Gaëtan Stoquart; Vincent Van Pesch; Souraya El Sankari; Christine Detrembleur; Thibault Warlop
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

2.  Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.

Authors:  Sarah D Broicher; Linard Filli; Olivia Geisseler; Nicole Germann; Björn Zörner; P Brugger; M Linnebank
Journal:  J Neurol       Date:  2018-02-20       Impact factor: 4.849

3.  Dalfampridine effects on cognition, fatigue, and dexterity.

Authors:  Melanie Korsen; Rhina Kunz; Ulf Schminke; Uwe Runge; Thomas Kohlmann; Alexander Dressel
Journal:  Brain Behav       Date:  2016-11-11       Impact factor: 2.708

4.  Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review.

Authors:  Michelle H Chen; Yael Goverover; Helen M Genova; John DeLuca
Journal:  CNS Drugs       Date:  2020-06       Impact factor: 5.749

5.  Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report.

Authors:  Mona Klara Ros Müller; Monika Christ; Markus Naumann; Antonios Bayas
Journal:  Ther Adv Neurol Disord       Date:  2022-03-29       Impact factor: 6.570

6.  Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis.

Authors:  Kateryna Schwartz; Nicholas F Wymbs; Hwa Huang; Maureen A Mealy; Carlos A Pardo; Kathleen Zackowski; Michael Levy
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-11-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.